|
Gene: PRR19 |
Gene summary for PRR19 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PRR19 | Gene ID | 284338 |
Gene name | proline rich 19 | |
Gene Alias | PRR19 | |
Cytomap | 19q13.2 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | A6NJB7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284338 | PRR19 | S014 | Human | Liver | HCC | 2.83e-27 | 7.43e-01 | 0.2254 |
284338 | PRR19 | S015 | Human | Liver | HCC | 6.83e-29 | 1.01e+00 | 0.2375 |
284338 | PRR19 | S016 | Human | Liver | HCC | 1.14e-37 | 9.66e-01 | 0.2243 |
284338 | PRR19 | S029 | Human | Liver | HCC | 1.62e-03 | 1.42e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRR19 | SNV | Missense_Mutation | c.95C>T | p.Ala32Val | p.A32V | A6NJB7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A1AH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | PD | ||
PRR19 | insertion | In_Frame_Ins | novel | c.211_212insTCACCACACCTGGCATCATCCAGCTAATTTTTATTTTTATTTTTTGTA | p.Ser70_Arg71insLeuThrThrProGlyIleIleGlnLeuIlePheIlePheIlePheCys | p.S70_R71insLTTPGIIQLIFIFIFC | A6NJB7 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
PRR19 | SNV | Missense_Mutation | novel | c.147N>G | p.Ile49Met | p.I49M | A6NJB7 | protein_coding | tolerated(0.26) | benign(0.192) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRR19 | SNV | Missense_Mutation | rs199545648 | c.62N>A | p.Arg21His | p.R21H | A6NJB7 | protein_coding | deleterious(0.03) | benign(0.104) | TCGA-XS-A8TJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
PRR19 | SNV | Missense_Mutation | novel | c.286G>A | p.Val96Met | p.V96M | A6NJB7 | protein_coding | deleterious(0.03) | benign(0.127) | TCGA-A6-2680-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRR19 | SNV | Missense_Mutation | c.653G>T | p.Ser218Ile | p.S218I | A6NJB7 | protein_coding | tolerated(0.17) | benign(0.001) | TCGA-A6-5659-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PRR19 | SNV | Missense_Mutation | c.472C>T | p.Pro158Ser | p.P158S | A6NJB7 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
PRR19 | SNV | Missense_Mutation | c.256N>A | p.Val86Ile | p.V86I | A6NJB7 | protein_coding | tolerated(0.17) | probably_damaging(0.991) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
PRR19 | SNV | Missense_Mutation | novel | c.709N>C | p.Phe237Leu | p.F237L | A6NJB7 | protein_coding | tolerated(1) | benign(0) | TCGA-CI-6620-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Ancillary | leucovorin | PD |
PRR19 | SNV | Missense_Mutation | rs554910146 | c.488N>A | p.Arg163Gln | p.R163Q | A6NJB7 | protein_coding | tolerated(0.08) | possibly_damaging(0.579) | TCGA-EI-6513-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |